Privia Health Group (Privia Health Group) Cash And Cash Equivalents : $351 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Privia Health Group Cash And Cash Equivalents?

Privia Health Group's quarterly cash and cash equivalents increased from Sep. 2023 ($330.39 Mil) to Dec. 2023 ($389.51 Mil) but then stayed the same from Dec. 2023 ($389.51 Mil) to Mar. 2024 ($351.14 Mil).

Privia Health Group's annual cash and cash equivalents increased from Dec. 2021 ($320.58 Mil) to Dec. 2022 ($347.99 Mil) and increased from Dec. 2022 ($347.99 Mil) to Dec. 2023 ($389.51 Mil).

Privia Health Group Cash And Cash Equivalents Historical Data

The historical data trend for Privia Health Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Privia Health Group Cash And Cash Equivalents Chart

Privia Health Group Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

46.89

84.63

320.58

347.99

389.51

Privia Health Group Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial														311.23	317.95	330.39	389.51	351.14

Privia Health Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Privia Health Group (NAS:PRVA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Privia Health Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Privia Health Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Privia Health Group (Privia Health Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Privia Health Group Inc (NAS:PRVA) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

950 N. Glebe Road, Suite 700, Arlington, VA, USA, 22203

Website

https://www.priviahealth.com

Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.

Executives

William M Sullivan	director	ONE PENN PLAZA, SUITE 5300, NY NY 10119
Thomas Bartrum	officer: EVP, General Counsel	950 N. GLEBE RD., SUITE 700, ALEXANDRIA VA 22203
Pamela O Kimmet	director	11207 ORANGE HIBISCUS LANE, PALM BEACH GARDENS FL 33418
David S Wichmann	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Parth Mehrotra	officer: President and COO	950 N. GLEBE RD., SUITE 700, ARLINGTON VA 22203
Adam Boehler	director	1215 5TH AVE N,, NASHVILLE TN 37208
Matthew Shawn Morris	director, officer: Chief Executive Officer	950 N. GLEBE ST., SUITE 700, ARLINGTON VA 22203
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Jeffrey Daniel Bernstein	director	200 WEST STREET, NEW YORK NY 10282
Pamplona Capital Partners Iii, L.p.	10 percent owner	94 SOLARIS AVENUE, CAMANA BAY, P.O. BOX 1348, GRAND CAYMAN E9 KY1-1108
Mbd Advisors, L.l.c.	10 percent owner	200 WEST STREET, NEW YORK NY 10282
David Mountcastle	officer: Chief Financial Officer	950 N. GLEBE RD., SUITE 700, ARLINGTON VA 22203
Jeffrey B Butler	director	950 N. GLEBE RD., SUITE 700, ARLINGTON VA 22101
David P King	director	PRIVIA HEALTH GROUP, INC., 950 N. GLEBE RD., SUITE 700, ARLINGTON VA 22203
Patricia Anne Maryland	director	7342 HORIZON DRIVE, WEST PALM BEACH FL 33412